In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck will develop Dov depression candidates

Executive Summary

Dov Pharmaceutical (in-licenses and develops compounds for treating CNS and CV diseases that involve alterations in neuronal processing) is licensing two clinical-phase triple uptake inhibitors to Merck for development against depression and other psychiatric illnesses. Dov's 8K of 9/22/04 adds that Merck also received rights of first refusal regarding another triple uptake inhibitor, DOV 102,677 (preclinical; for anxiety or depression) under certain circumstances and for additional payment.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies